ARTICLE | Clinical News
Claudiximab regulatory update
October 4, 2010 7:00 AM UTC
The COMP issued a positive opinion to grant Orphan Drug designation for Ganymed's claudiximab to treat gastric cancer. The mAb targeting cell surface antigen CLND18.2 is in Phase IIa testing to treat...